1 Tian, J. et al. Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc. Disord. 12, 70 (2012).
2 Lee, S. W. et al. Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients: the VENUS study. Circ. J. 76, 2662-2672 (2012).
3 Park, S. J. et al. Effect of statin treatment on modifying plaque composition: A double-blind, randomized study. J. Am. Coll. Cardiol. 67, 1772-1783 (2016).
4 Watanabe, T. et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J. Cardiol. 70, 537-544 (2017).
5 Ohwada, T. et al. Apolipoprotein B correlates with intra-plaque necrotic core volume in stable coronary artery disease. PLoS One. 14, e0212539 (2019).
6 Bosch, J. et al. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. Eur. Heart J. 42, 2995-3007 (2021).
7 Yusuf, S. et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N. Engl. J. Med. 374, 2021-2031 (2016).
8 Wyler von Ballmoos, M. C., Haring, B. & Sacks, F. M. The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis. J. Clin. Lipidol. 9, 498-510 (2015).
9 Scheffer, P. G. et al. Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn study. Clin. Chem. 54, 1325-1330 (2008).
10 Sacks, F. M. et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 102, 1886-1892 (2000).
11 Olivieri, O. et al. Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation. J. Thromb. Haemost. 8, 463-471 (2010).
12 Olivieri, O. et al. Increased incidence of ischemic cerebrovascular events in cardiovascular patients with elevated apolipoprotein CIII. Stroke. 51, 61-68 (2020).
13 Katzmann, J. L. et al. Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study. Lipids Health Dis. 19, 116 (2020).
14 Virmani, R., Burke, A. P., Farb, A. & Kolodgie, F. D. Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 47, C13-C18 (2006).
15 Olin-Lewis, K. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. J. Lipid Res. 43, 1969-1977 (2002).
16 Hiukka, A. et al. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes. 58, 2018-2026 (2009).
17 Gustafsson, M. & Borén, J. Mechanism of lipoprotein retention by the extracellular matrix. Curr. Opin. Lipidol. 15, 505-514 (2004).
18 Davidsson, P. et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J. Lipid Res. 46, 1999-2006 (2005).
19 Schissel, S. L. et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J. Biol. Chem. 273, 2738-2746 (1998).
20 Ruuth, M. et al. Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. Eur. Heart J. 39, 2562-2573 (2018).
21 Kawakami, A. et al. Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive g protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. Arterioscler. Thromb. Vasc. Biol. 27, 219-225 (2007).
22 Kawakami, A. et al. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 114, 681-687 (2006).
23 Niessner, A. & Weyand, C. M. Dendritic cells in atherosclerotic disease. Clin. Immunol. 134, 25-32 (2010).
24 Ohayon, J. et al. Necrotic core thickness and positive arterial remodeling index: Emergent biomechanical factors for evaluating the risk of plaque rupture. Am. J. Physiol. Heart Circ. Physiol. 295, H717-727 (2008).
25 Fujiwara, H., et al. Guidelines for elective percutaneous coronary intervention in patients with stable coronary artery disease (JCS 2011) published in 2012-digest version. Circ. J. 77, 1590-1607 (2013).
26 Mintz, G. S. et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 37, 1478-1492 (2001).
27 Muramatsu, T. et al. Reproducibility of intravascular ultrasound radiofrequency data analysis (virtual histology) with a 45-MHZ rotational imaging catheter in ex vivo human coronary arteries. J. Cardiol. 65, 134-142 (2015).